Danish vaccine developer Evaxion has released long-term data for its lead personalized cancer vaccine, with the shot scoring ...

An alliance of scientists at the Broad Institute and Bayer Pharmaceuticals have developed a drug candidate, sevabertinib, ...

In recent research, treatment with osimertinib plus a platinum–pemetrexed chemotherapy combination resulted in statistically ...

In the histology-centric world of cancer medicine, further work is needed to increase genomic testing rates and educate ...

Even after Merck & Co.’s Keytruda has climbed to the top of the industry’s sales charts and racked up dozens of FDA-a | A ...

"ESMO 2025: Anticipated Phase II data debut for Eikon’s NSCLC candidate" was originally created and published by Clinical ...

Welcome to The Pharma Letter’s real-time coverage of the 2025 European Society of Medical Oncology (ESMO) Congress, taking place October 17 to 21 in Berlin, Germany. This feed will deliver concise ...

Eikon Therapeutics, Inc., a late-stage clinical biopharmaceutical company dedicated to integrating advanced engineering with ...

Moderna faces significant uncertainty ahead of Q3 earnings, with heavy reliance on COVID vaccine revenues and limited ...

The company is studying the mRNA tumor-associated antigen vaccine as a monotherapy and in combination with Keytruda.

In a small phase II trial, radiation-free treatment with pembrolizumab (Keytruda) and platinum-based chemotherapy alone ...

Confirmation of 30mg efti as optimal biological dose relevant for Immutep’s oncology pipeline and potential future Biological License ...